poloxamine 701, 11111-34-5

Articles:

PubMed:	Poloxamine-cyclodextrin-simvastatin supramolecular systems promote osteoblast differentiation of mesenchymal stem cells.
PubMed:	Poloxamines for deswelling of organ-cultured corneas.
PubMed:	Osteogenic efficiency of in situ gelling poloxamine systems with and without bone morphogenetic protein-2.
PubMed:	Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering.
PubMed:	Poloxamine-based nanomaterials for drug delivery.
PubMed:	Moisture-activated rheological structuring of nonaqueous poloxamine-poly(acrylic acid) systems designed as novel biomedical implants.
PubMed:	Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption.
PubMed:	Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN).
PubMed:	Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908.
PubMed:	Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology.
PubMed:	Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation.
PubMed:	Re-establishing the long circulatory behaviour of poloxamine-coated particles after repeated intravenous administration: applications in cancer drug delivery and imaging.
PubMed:	Influence of the surfactant concentration on the body distribution of nanoparticles.
PubMed:	Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization.
PubMed:	Cloud point of nonionic surfactants: modulation with pharmaceutical excipients.
PubMed:	Humoral-mediated recognition of 'phagocyte-resistant' beads by lymph node macrophages of poloxamine-treated rats.
PubMed:	Modification of the copolymers poloxamer 407 and poloxamine 908 can affect the physical and biological properties of surface modified nanospheres.
PubMed:	Activation of the mononuclear phagocyte system by poloxamine 908: its implications for targeted drug delivery.
PubMed:	A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats.
PubMed:	Long circulating biodegradable poly(phosphazene) nanoparticles surface modified with poly(phosphazene)-poly(ethylene oxide) copolymer.
PubMed:	Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A 'hepatic-blockade' event or manipulation of nanosphere surface in vivo?
PubMed:	Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407.
PubMed:	Thermally gelling poloxamine Synperonic T908 solution as a vehicle for rectal drug delivery.
PubMed:	Polystyrene-poly (ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution.
PubMed:	Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats.
PubMed:	Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum.
PubMed:	An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen.
PubMed:	Effect of splenic congestion associated with haemolytic anaemia on filtration of 'spleen-homing' microspheres.
PubMed:	The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908.